ISSN 2831-4425
54 papers in the library · 210 citations · publishing 2022-2026
Psychedelic Medicine December 1, 2025 Tara Brach
By exploring the spiritual effects of psilocybin on clergy from a range of world religions, this study widens our view to consider the full evolutionary potential of the current psychedelic revolution. Throughout human history
Psychedelic Medicine October 8, 2025 Elise C. Tarbi, Skye A. Miner, Kabir Nigam et al. 1 citation
Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to meet these existential needs, yet little is known about how patients describe this element of their cancer journey, and how it might be affected by PAT, especially in the group therapy context. Purpose: To explore how patients with cancer and...
Psychedelic Medicine October 8, 2025 Pim B. van der Meer, Nout Schukking, Miranda G. Dik et al.
Background: Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) symptoms. In this systematic review, we aimed to assess the efficacy and safety of psychoactive tryptamines in patients with an SUD or non-substance-related disorder (i.e., gambling disorder) in order to provide a comprehensive overview of the available...
Psychedelic Medicine May 16, 2025 Roland R. Griffiths, William A. Richards, Robert L. Jesse et al. 14 citations
Background: Although historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduring effects of psilocybin in clergy....
Psychedelic Medicine April 28, 2025 Shakila Meshkat, Howell Fang, Rachel Sousa-Ho et al.
Introduction: High-dose psilocybin has shown potential in treating various psychiatric disorders, but its perceptual and cognitive effects, along with the risk of adverse events, highlight the need for alternative treatment approaches. One such approach is the use of low-dose psilocybin, which does not significantly alter cognition or perception. While low-dose psilocybin has garnered growing...
Psychedelic Medicine April 22, 2025 Sean M. Viña 6 citations
Objective: Prior research has found an association between psychedelic use and reduced stigma attached to mental illness. However, whether psychedelics alleviate stigma-related distress remains unclear. Since stigma impacts different groups uniquely, any moderating effect of psychedelics on stigma-related distress is likely to vary across subpopulations. This study addresses two main questions:...
Psychedelic Medicine April 21, 2025 Luke Flynn, Mary Rondeau, Martin Krsak et al. 1 citation
Introduction: Ketamine is an evidenced-based treatment for depression, and it has shown promise in addressing many other mental health conditions related to work-related stress or burnout, such as anxiety and post-traumatic stress disorder. Ketamine-assisted psychotherapy (KAP) is part of an emerging model of psychedelic medicine that employs psychoactive agents to support the psychotherapeutic...
Psychedelic Medicine April 14, 2025 Caroline Hayes
As the therapeutic potential of psychedelics is becoming more established, a wider range of compounds are beginning to be investigated for their antidepressant properties. 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) is one such example; its unusual properties may make it a more cost-effective and practical choice for health care providers. However, the same distinctive features may mean...
Psychedelic Medicine February 7, 2025 Jérémie Richard, Michael Levine 12 citations
The topic of psychological support and psychotherapy in the context of clinical investigations of psychedelic drugs is an often debated, yet predominantly unresolved issue in the field. Psychological support, as a concept, is poorly defined and there appears to be little agreement in the field regarding its essential components, boundaries and limits. While researchers have turned their...
Psychedelic Medicine January 21, 2025 Maria Helha Fernandes-Nascimento, Karine Viana-Ferreira, André Brooking Negrão 2 citations
Background: Psilocybin is a natural alkaloid with therapeutic potential in the treatment of different mental disorders. Bibliometric information on its use is still scattered in the literature. Objective: To investigate the temporal and bibliometric patterns of publications and the specificity of psilocybin in the treatment of mental disorders. Method: Performed a bibliometric analysis using...
Psychedelic Medicine January 20, 2025 Marianna Graziosi, Gabrielle Agin-Liebes, Mary P Cosimano et al. 9 citations
Introduction: Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for...
Psychedelic Medicine November 26, 2024 Nadav Liam Modlin, Tyler McPhee, Nira Zazon et al. 5 citations
Background: Psychedelics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine are increasingly recognized for their potential therapeutic benefits in treating complex and chronic mental health conditions. Growing public interest in psychedelics may drive increased consumption outside of medically supervised clinical trials. Correspondingly, legality issues and...
Psychedelic Medicine November 25, 2024 Noah D Gold, Broc A. Pagni, Petros Petridis et al. 3 citations
Background: Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is being actively studied for various psychiatric conditions, its effects on personal values in patients with alcohol use disorder (AUD) remain unexplored. This study examined the effects of PAT on personal values in patients with AUD and assessed...
Psychedelic Medicine November 18, 2024 Shakila Meshkat, Erica Kaczmarek, Zoe Doyle et al. 8 citations
Background: Bipolar II disorder (BD-II) is often associated with chronic and treatment resistant major depressive episodes. Psilocybin has shown promise for its rapid-acting antidepressant effects, though its impact on bipolar depression remains unexplored. In the present subgroup analysis of an already published trial on treatment-resistant depression (TRD), we aimed to preliminarily evaluate...
Psychedelic Medicine October 15, 2024 Thivya Turner, Paul Glue 1 citation
Background: The underlying mechanism(s) of action of psychedelic-assisted therapy (PAT) to reduce distress, depression, and/or anxiety symptoms in life-threatening illness are poorly understood. It has been postulated that addressing death anxiety, and components of spiritual and existential distress, may be mediating factors. Method: This systematic review describes the current evidence base...
Psychedelic Medicine September 1, 2024 Albert Garcia‐romeu
Rationale: N-methyl-D-aspartate receptor-mediated dissociatives and serotonergic hallucinogens are being increasingly used in therapeutic interventions that involve nonordinary states of consciousness and may represent a unique mental health paradigm wherein pharmacologically induced experiences are conducive to psychological well-being. Objective: The aim of this study was to further...
Psychedelic Medicine May 8, 2024 Susanna Myers, John Guy, Anthony L. Back et al. 7 citations
For a new clinical trial testing a group retreat-based format of psilocybin-assisted therapy, our research team created an initial set of practice guidelines that aimed to describe facilitator use of touch in a way that is ethical, supportive, and minimizes harm. In our first three retreats, however, we had two unexpected experiences with touch that led us to iterate our initial guidelines into...
Psychedelic Medicine May 3, 2024 correction
[This corrects the article DOI: 10.1089/psymed.2022.0002.].
Psychedelic Medicine February 28, 2024 Dana D. DiRenzo, Jamie Perin, Erika Darrah et al. 4 citations
This preliminary study suggests that a transient increase in cytokine production ≤1-week postpsilocybin may be found, although not consistently across patient populations. More broadly, peripheral cytokine production is possibly altered by psilocybin administration. ClinicalTrials.gov Identifier: NCT01988311.
Psychedelic Medicine February 28, 2024 Joshua Woolley, Amanda E. Downey, Ellen Bradley et al. 2 citations
Balancing the need for effective treatments against the potential for serious adverse events in those undergoing psilocybin therapy with a family history of BD, we argue for caution in psychedelic clinical trials but not outright exclusion of these individuals. Our risk stratification tool allows for more nuanced inclusion and exclusion criteria.
Psychedelic Medicine December 1, 2023 Julia Malicki, Amelia Baltes, Christopher R. Nicholas et al. 7 citations
Coadministration of psilocybin and buprenorphine was safely tolerated and did not demonstrate contraindicating effects vis-à-vis effectiveness of buprenorphine or the subjective effects of psilocybin. Challenges in feasibility led to modifications in the sample population and eligibility criteria and strategies to improve accessibility, minimize burden, and enhance overall...
Psychedelic Medicine September 6, 2023 Marc J. Weintraub, Jessica K Jeffrey, Charles S. Grob et al. 4 citations
The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomized clinical trials to test the effects of PA-CBT for patients with depression and other mental health conditions, as well as hypotheses concerning mediating mechanisms at the cognitive and affective levels. ClinicalTrials.gov ID: NCT05227612.
Psychedelic Medicine August 30, 2023 Samantha Hilbert, David S. Mathai, Nathan D. Sepeda et al. 10 citations
This analysis suggests the utility of exploring clinical applications of dissociatives that occur within the supportive contexts that are characteristic of psychedelic research and that prioritize the optimization of psychologically valuable drug experiences. This study was registered with ClinicalTrials.gov (NCT02033707).
Psychedelic Medicine August 18, 2023 Philip Kamilar-Britt, Elana B. Gordis, Mitch Earleywine 15 citations
Clinical trials support the promise of psychedelic-assisted therapy (PAT) and reveal potential mechanisms underlying efficacy. Out of necessity, initial studies of PAT have focused on feasibility and impact with special attention to acute responses to the molecules, but investigations of the psychotherapy components of PAT have lagged other work. Years of research on other forms of...
Psychedelic Medicine August 18, 2023 Claudia Lex, Antonio F. Pagán, Jair C Soares et al. 9 citations
Background: Psilocybin and psychedelic-assisted therapy (PAT) have gained renewed interest due to recent findings that PAT can enhance therapeutic outcomes. In 2019, the U.S. Food & Drug Administration (FDA) approved breakthrough therapy status to psilocybin for the treatment of depression, but PAT has yet to be approved as a therapeutic treatment for mental health disorders. Should the FDA...